Mechanistic description
We propose that GBA deficiency-driven accumulation of glucosylceramide (GlcCer) in lysosomal membranes creates ordered lipid raft-like microdomains that serve as high-affinity nucleation sites for alpha-synuclein (αSyn) binding and fibrillization. The resultant αSyn oligomers directly interact with LIMP-2 (SCARB2), the mannose-6-phosphate receptor responsible for trafficking pro-GBA from ER to lysosome, impairing its function and causing further GBA mislocalization. This creates a self-reinforcing bidirectional loop. Testable prediction: pharmacological reduction of GlcCer via GZ/SAR402671 will reduce αSyn seeding susceptibility in patient-derived neurons, measured by ThT fluorescence and seeding assays, prior to detectable changes in total αSyn levels. Blocking this lipid-mediated nucleation interface would break the loop upstream of both aggregation and trafficking impairment.
Mechanism / pathway
- GBA
- Lysosomal glucosylceramide metabolism and alpha-synuclein nucleation
- Parkinson's disease
Evidence for (5)
Genetics and Pathogenesis of Parkinson's Syndrome.
Parkinson's disease: etiopathogenesis and treatment.
Parkinson's Disease Genetics and Pathophysiology.
GBA Variants and Parkinson Disease: Mechanisms and Treatments.
Parkinson's disease.
Evidence against (2)
GBA1 deficiency triggers alpha-synuclein aggregation primarily through direct lysosomal hydrolase failure and impaired chaperone-mediated autophagy (CMA), rather than through GlcCer-mediated lipid raft formation; CMA disruption can promote synuclein aggregation without GlcCer accumulation
GBA1 variants with residual enzyme activity show alpha-synuclein accumulation disproportionate to GlcCer levels, indicating that the lipid raft nucleation model oversimplifies the GBA-synuclein relationship and that other GBA-interacting factors contribute independently
Evidence matrix
Supporting
- Genetics and Pathogenesis of Parkinson's Syndrome. PMID:36100231 · 2023 · Annu Rev Pathol
- Parkinson's disease: etiopathogenesis and treatment. PMID:32576618 · 2020 · J Neurol Neurosurg Psychiatry
- Parkinson's Disease Genetics and Pathophysiology. PMID:34236893 · 2021 · Annu Rev Neurosci
- GBA Variants and Parkinson Disease: Mechanisms and Treatments. PMID:35455941 · 2022 · Cells
- Parkinson's disease. PMID:19524782 · 2009 · Lancet
Contradicting
- GBA1 deficiency triggers alpha-synuclein aggregation primarily through direct lysosomal hydrolase failure and impaired chaperone-mediated autophagy (CMA), rather than through GlcCer-mediated lipid raft formation; CMA disruption can promote synuclein aggregation without GlcCer accumulation PMID:41465169 · 10.3390/ijms26083669
- GBA1 variants with residual enzyme activity show alpha-synuclein accumulation disproportionate to GlcCer levels, indicating that the lipid raft nucleation model oversimplifies the GBA-synuclein relationship and that other GBA-interacting factors contribute independently PMID:38347286 · 10.3390/ijms25031567
Bayesian persona consensus
scidex.consensus.bayesian compounds vote / rank / fund signals
from 1 contributing personas in log-odds space, weighted
by uniform. Prior 50%.
Cite this hypothesis
Cite this hypothesis
etl-backfill (2026). Glucosylceramide accumulation nucleates alpha-synuclein aggregation via lipid r…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-2b545285ee
@misc{scidex_hypothesis_h2b54528,
title = {Glucosylceramide accumulation nucleates alpha-synuclein aggregation via lipid r…},
author = {etl-backfill},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-2b545285ee},
note = {SciDEX artifact hypothesis:h-2b545285ee}
}